Ureidopyridazine derivatives as acyl-CoA:cholesterol acyltransferase inhibitors

Scientia Pharmaceutica

Volumn 74, Issue 3, 2006, Pages 85-97

  Gelain, Arianna ^a   Bettinelli, Ilaria ^a   Barlocco, Daniela ^a   Kwon, Byoung Mog ^b   Jeong, Tae Sook ^b   Im, Kyung Ran ^b   Legnani, Laura ^c   Toma, Lucio ^c  

^a UNIVERSITY OF MILAN   (Italy)

^b Korea Research Institute of Bioscience and Biotechnology (KRIBB)   (South Korea)

^c UNIVERSITY OF PAVIA   (Italy)

Author keywords

ACAT inhibitors; Hypercholesterolemia; Pyridazine derivatives; Ureido derivatives

Indexed keywords

ACYL COENZYME A; CHOLESTEROL ACYLTRANSFERASE INHIBITOR; N (2,4 DIFLUOROPHENYL) N' HEPTYL N'{4 [PYRIDAZIN 3 YL)THIO]PENTYL}UREA DERIVATIVE; PYRIDAZINE DERIVATIVE; SULFONE DERIVATIVE; UNCLASSIFIED DRUG; UREA DERIVATIVE; UREIDOPYRIDAZINE DERIVATIVE;

ANIMAL CELL; ARTICLE; CALCULATION; DRUG ACTIVITY; DRUG INHIBITION; DRUG STRUCTURE; LIVER MICROSOME; NONHUMAN; RAT; STRUCTURE ACTIVITY RELATION;

EID: 33750689478     PISSN: 00368709     EISSN: 22180532     Source Type: Journal    
DOI: 10.3797/scipharm.2006.74.85     Document Type: Article

References (16)

1. American Heart Associaton. 1999 Heart and Stroke Statistical Update. Dallas, TX. American Heart Association, 1998.
2. Norata G D, Catapano A L. Lipid lowering activity of drugs affecting cholesterol absorption. Nutr. Metab. Cardiovas. Dis. 2004;14:42-51.
3. Kushwaha R S, Vandeberg J F, Rodriguez R, Vandeberg J L. Cholesterol absorption and hepatic acyl-coenzyme A:cholesterol acyltransferase activity play major roles in lipemic response to dietary cholesterol and fat in laboratory opossums. Metabolism 2004;53:817-22.
4. Chang CCY, Lee C G, Chang E T, Cruz J C, Levesque M C, Chang T Y. Recombinant acyl-CoA:cholesterol acyltransferase-1 (ACAT-1) purified to essential homogeneity utilizes cholesterol in mixed micelles or in vesicles in a highly cooperative manner. J. Biol. Chem. 1998;273:35132-41.
5. Joyce C, Skinner K, Anderson R A, Rudel L L. Acyl-coenzyme A:cholesteryl acyltransferase 2. Curr. Opin. Lipidol. 1999;10:89-95.
6. Carlos L, Hill S H, Wasan M W. Potential role of acyl-Coenzyme A:cholesterol transferase (ACAT) inhibitors as hypolipidemic and atherosclerosis drugs. Pharm. Res. 2005;22:1578-88.
7. Giovannoni M P, Dal Piaz V, Kwon B M, Kim M K, Kim Y K, Toma L, Barlocco D, Bernini F, Canavesi M. 5,6-Diphenylpyridazine derivatives as acyl-CoA:cholesterol acyltransferase inhibitors. J. Med. Chem. 2001;44:4292-5.
8. Toma L, Nava D, Celentano G, Giovannoni M P, Dal Piaz V, Kwon B M, Kim M K, Kim Y K, Barlocco D. 5,6-Dinitrophenyl and 5-aminophenyl-6-nitrophenyl analogues of the ACAT inhibitor 5,6-diphenyl-3-alkylaminopyridazines. Heterocycle's 2000;53:2709-18.
9. Toma L, Giovannoni M P, Dal Piaz V, Kwon B M, Kim Y K, Gelain A, Barlocco D. Mono- and di-substituted 5,6-diphenyl-3-alkylamino-pyridazines active as ACAT inhibitors. Heterocycles 2002;57:39-46.
10. Toma L, Giovannoni M P, Vergelli C, Dal Piaz V, Kwon B M, Kim Y K, Gelain A, Barlocco D. Novel 3-arylamino-and 3-cycloalkylamino-5,6-diphenyl-piridazines active as ACAT inhibitors. Arch. Pharm. Pharm. Med. Chem. 2002;11:563-6.
11. Gelain A. Pyridazine derivatives as novel acyl-CoA:cholesterol acyltransferase (ACAT) inhibitors. J. Heterocyclic Chem. 2005;42:395-400.
12. Higley C A, Wilde R G, Maduskuie T P, Johnson A L, Pennev P, Billheime J T, Robinson C S, Gilles P J, Wexler R R. Acyl CoA: cholesterol acyltransferase (ACAT) inhibitors: synthesis and structure-activity relationship studies of a new series of trisubstituted imidazoles. J. Med. Chem. 1994;37:3511-22.
13. Coates W J, McKillop A. One-pot preparation of 6-substituted 3(2H)-pyridazinones from ketones. Synthesis 1993;3:334-42.
14. Wermuth C G, Bourguignon J J, Schiewer G, Gies J P, Schoenfelder A, Melikian A, Bouchet M J, Chantreux D, Molimard J C, Heaulme M. Synthesis and structure-activity relationships of a series of aminopyridazine derivatives of γ-aminobutyric acid acting as selective GABA-A antagonists. J. Med. Chem. 1987;30:239-49.
15. Jeong T S, Kim S U, Son K H, Kwon Y K, Choi M U, Bok S H. GERI-BP001 compounds, new inhibitors of acyl-CoA:cholesterol acyltransferase from Aspergillus fumigatus F37 I. Production, isolation and physico-chemical and biological properties. J. Antibiotics 1995;48:751-6.
16. Frisch M J, Trucks G W, Schlegel H B, Scuseria G E, Robb M A, Cheeseman J R, Montgomery Jr J A, Vreven T, Kudin K N, Burant J C, Millam J M, Iyengar S S, Tomasi J, Barone V, Mennucci B, Cossi M, Scalmani G, Rega N, Petersson G A, Nakatsuji H, Hada M, Ehara M, Toyota K, Fukuda R, Hasegawa J, Ishida M, Nakajima T, Honda Y, Kitao O, Nakai H, Klene M, Li X, Knox J E, Hratchian H P, Cross J B, Adamo C, Jaramillo J, Gomperts R, Stratmann R E, Yazyev O, Austin A J, Cammi R, Pomelli C, Ochterski J W, Ayala P Y, Morokuma K, Voth G A, Salvador P, Dannenberg J J, Zakrzewski V G, Dapprich S, Daniels A D, Strain M C, Farkas O, Malick D K, Rabuck A D, Raghavachari K, Foresman J B, Ortiz J V, Cui Q, Baboul A G, Clifford S, Cioslowski J, Stefanov B B, Liu G, Liashenko A, Piskorz P, Komaromi I, Martin R L, Fox D J, Keith T, Al-Laham M A, Peng C Y, Nanayakkara A, Challacombe M, Gill PMW, Johnson B, Chen W, Wong M W, Gonzalez C, Pople J A. Gaussian 03, Revision B.02, In: Gaussian, Inc., Pittsburgh PA, 2003.